Almost half of pediatric trials don’t publish or report outcomes, examine finds

March 22, 2022

2 min learn

Disclosures: Bourgeois experiences no related monetary disclosures. Please see the examine for all authors’ related monetary disclosures.

Almost half of pediatric medical trials initiated over a greater than 12-year interval didn’t report or publish their outcomes, in accordance with a examine printed in Pediatrics.

Researchers carried out a cross-sectional evaluation of 13,259 medical trials that enrolled contributors aged 18 years or youthful from October 2007 to March 2020.

Almost half of all initiated pediatric medical trials don’t report outcomes, in accordance with a examine in Pediatrics. Supply: Adobe Inventory

“The panorama of pediatric medical trials, together with drivers of completion and well timed dissemination of outcomes, is just not properly understood,” they wrote. “We aimed to characterize the prevalence of and elements related to early discontinuation, outcomes reporting, and publication of pediatric medical trials.”

They discovered that 11.1% of the trials have been stopped early, with recruitment failure famous as a predominant purpose for discontinuation. Solely round half (51.2%) reached completion, reported outcomes or acquired publication.

Authorities-sponsored trials (adjusted OR = 0.72; 95% CI, 0.47-0.97) and educational trials (aOR = 0.64; 95% CI, 0.5-0.82) have been much less prone to be discontinued in contrast with trade trials. Authorities (aOR = 1.94; 95% CI, 1.52-2.48) and educational (aOR = 1.61; 95% CI, 1.35-1.92) trials additionally have been extra prone to be printed than trade trials. The researchers additionally discovered that educational trial investigators have been the least prone to report outcomes (aOR = 0.34; 95% CI, 0.31-0.52).

“Though there are encouraging current developments, challenges with the completion and well timed reporting and publication of pediatric trial outcomes persist,” the researchers wrote. “Our examine outcomes are considerably related to essential trial traits, comparable to funding supply. Because the pediatric medical trial ecosystem expands, so too should the mechanisms to deal with distinctive moral, financial, and epidemiological limitations be prioritized.”

The examine was accompanied by a commentary from Florence T. Bourgeois, MD, MPH, an affiliate professor of pediatrics at Harvard Medical Faculty and director of the Pediatric Therapeutics and Regulatory Science Initiative at Boston Kids’s Hospital.

“It’s tough to completely gauge the inefficiencies and loss this discontinuation fee represents and not using a higher understanding of the sources invested in these trials or the variety of contributors enrolled in research that did not yield scientific findings,” Borgeois wrote. “Nonetheless, it supplies a reference throughout a broad cohort of pediatric trials and confirms the continued problem of recruiting pediatric contributors to medical trials.”

To behave on the findings, the commentary says, researchers should construct consensus on key options and trial outcomes “deemed important to maximizing sources and advancing pediatric medical care,” which might embody measures of trial discontinuation, outcomes reporting, and information sharing and reuse.

“Utilizing a normal set of metrics, a data-driven strategy could possibly be utilized to monitoring actions and directing modification and strengthening of analysis infrastructures, governing insurance policies, and funding methods,” Bourgeois wrote. “Formalizing ongoing analysis would supply the wanted instruments to effectively advance pediatric medical trial infrastructures and maximize advantages to little one well being.”


Bourgeois F, et al. Pediatrics. 2022; doi: 10.1542/peds.2021-055815.


Leave a Reply